Summary
Global Markets Direct’s, ‘Malaria - Pipeline Review, H1 2016’, provides an overview of the Malaria pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Malaria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Malaria and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Malaria
- The report reviews pipeline therapeutics for Malaria by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Malaria therapeutics and enlists all their major and minor projects
- The report assesses Malaria therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Malaria
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Malaria
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Malaria pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
4SC AG
Acetylon Pharmaceuticals, Inc.
Actelion Ltd
Agilvax, Inc.
Akshaya Bio Inc.
Amura Holdings Limited
Artificial Cell Technologies, Inc.
AstraZeneca Plc
Bharat Biotech International Limited
Callaghan Innovation Research Ltd.
Carna Biosciences, Inc.
CEL-SCI Corporation
Celgene Corporation
Cellceutix Corporation
Chong Kun Dang Pharmaceutical Corp.
Cilian AG
Daiichi Sankyo Company, Limited
DesignMedix, Inc.
Eisai Co., Ltd.
Genocea Biosciences, Inc.
GenVec, Inc.
Genzyme Corporation
GlaxoSmithKline Plc
Hager Biosciences, LLC
iBio, Inc.
Imaxio SA
Immtech Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.
IPCA Laboratories Limited
IRBM Science Park SpA
Jenrin Discovery, Inc.
Jomaa Pharma GmbH
Kancera AB
Lipocure Ltd.
Lipotek Pty Ltd.
LondonPharma Ltd
Merck KGaA
MerLion Pharmaceuticals Pte Ltd
Microbiotix, Inc.
Mucosis B.V.
Mymetics Corporation
Novartis AG
PaxVax, Inc.
Pfenex Inc.
Pfizer Inc.
Protein Potential, LLC
Raptor Pharmaceutical Corp.
Rodos BioTarget GmbH
Sanaria Inc.
Sanofi
SATT Lutech SAS
SBI Pharmaceuticals Co., Ltd.
SEEK Group
Selecta Biosciences, Inc.
Sigma-Tau S.p.A.
Takeda Pharmaceutical Company Limited
Telormedix SA
Tomegavax, Inc.
VLP Biotech, Inc.
Zydus Cadila Healthcare Limited
'
Table of Contents
Table of Contents 2
Introduction 6
Malaria Overview 7
Therapeutics Development 8
Malaria - Therapeutics under Development by Companies 10
Malaria - Therapeutics under Investigation by Universities/Institutes 15
Malaria - Pipeline Products Glance 19
Malaria - Products under Development by Companies 23
Malaria - Products under Investigation by Universities/Institutes 30
Malaria - Companies Involved in Therapeutics Development 36
Malaria - Therapeutics Assessment 96
Drug Profiles 107
Malaria - Recent Pipeline Updates 355
Malaria - Dormant Projects 378
Malaria - Discontinued Products 389
Malaria - Product Development Milestones 391
Appendix 400
List of Tables
Number of Products under Development for Malaria, H1 2016 30
Number of Products under Development for Malaria - Comparative Analysis, H1 2016 31
Number of Products under Development by Companies, H1 2016 32
Number of Products under Development by Companies, H1 2016 (Contd..1) 33
Number of Products under Development by Companies, H1 2016 (Contd..2) 34
Number of Products under Development by Companies, H1 2016 (Contd..3) 35
Number of Products under Development by Companies, H1 2016 (Contd..4) 36
Number of Products under Investigation by Universities/Institutes, H1 2016 37
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 38
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 39
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..3) 40
Comparative Analysis by Late Stage Development, H1 2016 41
Comparative Analysis by Clinical Stage Development, H1 2016 42
Comparative Analysis by Early Stage Development, H1 2016 43
Comparative Analysis by Unknown Stage Development, H1 2016 44
Products under Development by Companies, H1 2016 45
Products under Development by Companies, H1 2016 (Contd..1) 46
Products under Development by Companies, H1 2016 (Contd..2) 47
Products under Development by Companies, H1 2016 (Contd..3) 48
Products under Development by Companies, H1 2016 (Contd..4) 49
Products under Development by Companies, H1 2016 (Contd..5) 50
Products under Development by Companies, H1 2016 (Contd..6) 51
Products under Investigation by Universities/Institutes, H1 2016 52
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 53
Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 54
Products under Investigation by Universities/Institutes, H1 2016 (Contd..3) 55
Products under Investigation by Universities/Institutes, H1 2016 (Contd..4) 56
Products under Investigation by Universities/Institutes, H1 2016 (Contd..5) 57
Malaria - Pipeline by 4SC AG, H1 2016 58
Malaria - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016 59
Malaria - Pipeline by Actelion Ltd, H1 2016 60
Malaria - Pipeline by Agilvax, Inc., H1 2016 61
Malaria - Pipeline by Akshaya Bio Inc., H1 2016 62
Malaria - Pipeline by Amura Holdings Limited, H1 2016 63
Malaria - Pipeline by Artificial Cell Technologies, Inc., H1 2016 64
Malaria - Pipeline by AstraZeneca Plc, H1 2016 65
Malaria - Pipeline by Bharat Biotech International Limited, H1 2016 66
Malaria - Pipeline by Callaghan Innovation Research Ltd., H1 2016 67
Malaria - Pipeline by Carna Biosciences, Inc., H1 2016 68
Malaria - Pipeline by CEL-SCI Corporation, H1 2016 69
Malaria - Pipeline by Celgene Corporation, H1 2016 70
Malaria - Pipeline by Cellceutix Corporation, H1 2016 71
Malaria - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 72
Malaria - Pipeline by Cilian AG, H1 2016 73
Malaria - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 74
Malaria - Pipeline by DesignMedix, Inc., H1 2016 75
Malaria - Pipeline by Eisai Co., Ltd., H1 2016 76
Malaria - Pipeline by Genocea Biosciences, Inc., H1 2016 77
Malaria - Pipeline by GenVec, Inc., H1 2016 78
Malaria - Pipeline by Genzyme Corporation, H1 2016 79
Malaria - Pipeline by GlaxoSmithKline Plc, H1 2016 80
Malaria - Pipeline by Hager Biosciences, LLC, H1 2016 81
Malaria - Pipeline by iBio, Inc., H1 2016 82
Malaria - Pipeline by Imaxio SA, H1 2016 83
Malaria - Pipeline by Immtech Pharmaceuticals, Inc., H1 2016 84
Malaria - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 85
Malaria - Pipeline by IPCA Laboratories Limited, H1 2016 86
Malaria - Pipeline by IRBM Science Park SpA, H1 2016 87
Malaria - Pipeline by Jenrin Discovery, Inc., H1 2016 88
Malaria - Pipeline by Jomaa Pharma GmbH, H1 2016 89
Malaria - Pipeline by Kancera AB, H1 2016 90
Malaria - Pipeline by Lipocure Ltd., H1 2016 91
Malaria - Pipeline by Lipotek Pty Ltd., H1 2016 92
Malaria - Pipeline by LondonPharma Ltd, H1 2016 93
Malaria - Pipeline by Merck KGaA, H1 2016 94
Malaria - Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2016 95
Malaria - Pipeline by Microbiotix, Inc., H1 2016 96
Malaria - Pipeline by Mucosis B.V., H1 2016 97
Malaria - Pipeline by Mymetics Corporation, H1 2016 98
Malaria - Pipeline by Novartis AG, H1 2016 99
Malaria - Pipeline by PaxVax, Inc., H1 2016 100
Malaria - Pipeline by Pfenex Inc., H1 2016 101
Malaria - Pipeline by Pfizer Inc., H1 2016 102
Malaria - Pipeline by Protein Potential, LLC, H1 2016 103
Malaria - Pipeline by Raptor Pharmaceutical Corp., H1 2016 104
Malaria - Pipeline by Rodos BioTarget GmbH, H1 2016 105
Malaria - Pipeline by Sanaria Inc., H1 2016 106
Malaria - Pipeline by Sanofi, H1 2016 107
Malaria - Pipeline by SATT Lutech SAS, H1 2016 108
Malaria - Pipeline by SBI Pharmaceuticals Co., Ltd., H1 2016 109
Malaria - Pipeline by SEEK Group, H1 2016 110
Malaria - Pipeline by Selecta Biosciences, Inc., H1 2016 111
Malaria - Pipeline by Sigma-Tau S.p.A., H1 2016 112
Malaria - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 113
Malaria - Pipeline by Telormedix SA, H1 2016 114
Malaria - Pipeline by Tomegavax, Inc., H1 2016 115
Malaria - Pipeline by VLP Biotech, Inc., H1 2016 116
Malaria - Pipeline by Zydus Cadila Healthcare Limited, H1 2016 117
Assessment by Monotherapy Products, H1 2016 118
Assessment by Combination Products, H1 2016 119
Number of Products by Stage and Target, H1 2016 121
Number of Products by Stage and Mechanism of Action, H1 2016 124
Number of Products by Stage and Route of Administration, H1 2016 126
Number of Products by Stage and Molecule Type, H1 2016 128
Malaria Therapeutics - Recent Pipeline Updates, H1 2016 377
Malaria - Dormant Projects, H1 2016 400
Malaria - Dormant Projects (Contd..1), H1 2016 401
Malaria - Dormant Projects (Contd..2), H1 2016 402
Malaria - Dormant Projects (Contd..3), H1 2016 403
Malaria - Dormant Projects (Contd..4), H1 2016 404
Malaria - Dormant Projects (Contd..5), H1 2016 405
Malaria - Dormant Projects (Contd..6), H1 2016 406
Malaria - Dormant Projects (Contd..7), H1 2016 407
Malaria - Dormant Projects (Contd..8), H1 2016 408
Malaria - Dormant Projects (Contd..9), H1 2016 409
Malaria - Dormant Projects (Contd..10), H1 2016 410
Malaria - Discontinued Products, H1 2016 411
Malaria - Discontinued Products (Contd..1), H1 2016 412
List of Figures
Number of Products under Development for Malaria, H1 2016 30
Number of Products under Development for Malaria - Comparative Analysis, H1 2016 31
Number of Products under Development by Companies, H1 2016 32
Number of Products under Investigation by Universities/Institutes, H1 2016 37
Comparative Analysis by Late Stage Development, H1 2016 41
Comparative Analysis by Clinical Stage Development, H1 2016 42
Comparative Analysis by Early Stage Products, H1 2016 43
Assessment by Monotherapy Products, H1 2016 118
Assessment by Combination Products, H1 2016 119
Number of Products by Top 10 Targets, H1 2016 120
Number of Products by Stage and Top 10 Targets, H1 2016 120
Number of Products by Top 10 Mechanism of Actions, H1 2016 123
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 123
Number of Products by Routes of Administration, H1 2016 125
Number of Products by Stage and Routes of Administration, H1 2016 125
Number of Products by Top 10 Molecule Types, H1 2016 127
Number of Products by Stage and Top 10 Molecule Types, H1 2016 127
